Nature is pleased to acknowledge financial support from Alexion Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc., and grants from Shire plc and BioMarin Pharmaceuticals, Inc. in producing this Outlook. As always, Nature retains sole responsibility for all editorial content.